Evidence map›Paper›PMID 42056379›Full record

ArticleBritish journal of cancer2026

Identification of a distinct cluster of LY6E

Kun Chen, Jianjiao Ni, Yida Li, Sijia Gu, Ye Li, Xi Yang, Shyamal Goswami, Qiyu Luo, Yalei Zhang, Ling Qian and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kun Chen *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jianjiao Ni *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yida Li *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Sijia Gu *Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ye Li *Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xi Yang *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shyamal Goswami *Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China.
Qiyu LuoDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yalei ZhangDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ling QianDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yudi HuDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Runye ZhouDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yating WangDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingjing LiuDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiuyu CaiDepartment of VIP Inpatient, Sun Yet-Sen University Cancer Center, Guangdong Provincial Clinical Research Center for Cancer, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Chunrong ZhangDepartment of Thoracic Surgery, Nantong Tumor Hospital, Jiangsu, China.
Saifullah AfridiMolecular Oncology Laboratory, Vaccine and Drug Development Biotechnology Research Group, VPCLS, TUBİTAK Marmara Research Center, Kocaeli, Istanbul, Turkey.
Yi ChenDepartment of Clinical Laboratory Shanghai East Hospital, Tongji University, Shanghai, China.
Peng WangDepartment of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. peng_wang@fudan.edu.cn.ORCID http://orcid.org/0000-0003-0569-9001
Zhengfei ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. fuscczzf@163.com.ORCID http://orcid.org/0000-0001-7537-3619

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81872461
6 · The paper itself

Abstract

backgroundTumor-associated macrophages are key players in cancer progression, but their heterogeneity is not fully understood. This study aims to investigate the role of a specific macrophage subpopulation marked by LY6E in esophageal squamous cell carcinoma (ESCC).

methodsWe analyzed macrophage subsets in ESCC, focusing on LY6E

resultsA distinct LY6E

conclusionsOur findings reveal a critical and complex role for LY6E

Indexed as

Antigens, LyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaMacrophagesTumor-Associated MacrophagesCD8-Positive T-LymphocytesFemaleHumansImmunotherapyMalePhenotypePrognosisAntigens, Ly

Identifiers

PMID42056379
PMCPMC13372808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.